reference/7991180

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7991180

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Comparative Study\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	1289
issn	1477-0970 1352-4585
issueIdentifier	9
pageRange	1278-1289
publicationName	Multiple sclerosis (Houndmills, Basingstoke, England)
startingPage	1278
bibliographicCitation	Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, Bar-Or A, Traboulsee AL, Reiman LE, O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012 Sep;18(9):1278–89. PMID: 22307384; PMCID: PMC3573681.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aef0949483f9fa4011b5204c82550b5a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b8a82fe1238a3dc2b277885567806d5d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8285138d7f14a43bfaeb78e0f9179ce8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8d1b1ec92bbcb4c564c83a6de0ee599c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_45d081d7cc0eac6ec03878807f0ceed5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_08b5201b309fe13f9a1108bc098da1b1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eb5d1526f10c9f2a474b203dbdef27a4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ee1c8bbe7fb96eaad6ed26772e2fbd66 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b9f3d0446fab8a771b05cbed977eec66 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_faaa4d9c8fe5e33af38520f2385c3bf5
date	2012-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC3573681 https://doi.org/10.1177/1352458512436594 https://pubmed.ncbi.nlm.nih.gov/22307384
isPartOf	https://portal.issn.org/resource/ISSN/1352-4585 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/20508 https://portal.issn.org/resource/ISSN/1477-0970
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
discusses	http://id.nlm.nih.gov/mesh/M0010750 http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0011157 http://id.nlm.nih.gov/mesh/M0021643 http://id.nlm.nih.gov/mesh/M0519665 http://id.nlm.nih.gov/mesh/M0005360
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D014052Q000008 http://id.nlm.nih.gov/mesh/D003437Q000008 http://id.nlm.nih.gov/mesh/D007155Q000008 http://id.nlm.nih.gov/mesh/D020529Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D005500 http://id.nlm.nih.gov/mesh/D011788 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D007155Q000009 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D013997 http://id.nlm.nih.gov/mesh/D006885 http://id.nlm.nih.gov/mesh/D009570 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D011237 http://id.nlm.nih.gov/mesh/D003437Q000009 http://id.nlm.nih.gov/mesh/D008279 http://id.nlm.nih.gov/mesh/D014052Q000009 http://id.nlm.nih.gov/mesh/D004185 http://id.nlm.nih.gov/mesh/D020529Q000175 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D020529Q000523 http://id.nlm.nih.gov/mesh/D000284
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54684141 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8153 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_aeebd1980c6662678028fc899ba441eb http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7507 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8532 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8703 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129046631 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128672523

Total number of triples: 73.